N-(3-methylsulfanylphenyl)-9H-pyrido[2,3-b]indol-4-amine | 1600515-47-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(3-methylsulfanylphenyl)-9H-pyrido[2,3-b]indol-4-amine
• CAS: 1600515-47-6
• 化学式: C₁₈H₁₅N₃S
• 分子量: 305.403
• InChiKey: HNKGWWVVBQVBKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9H-吡啶并[2,3-B]吲哚 在 双氧水 、 溶剂黄146 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.5h， 生成 N-(3-methylsulfanylphenyl)-9H-pyrido[2,3-b]indol-4-amine
  参考文献：
  名称：

  Discovery of 4-anilino α-carbolines as novel Brk inhibitors

  摘要：

  Dysregulation of cell signalling processes caused by an enhanced activity of protein kinases mainly contributes to cancer progression. Protein kinase inhibitors have been established as promising drugs that inhibit such overactive protein kinases in cancer cells. The formation of metastases, which makes a therapy difficult, remains a great challenge for cancer treatment. Recently, breast tumor kinase (Brk) was discovered as novel and interesting target for a cancer therapy because Brk participates in both cell dysregulation and metastasis. We discovered 4-anilino substituted a-carboline compounds as a novel class of highly active Brk inhibitors. In the current work, structure-activity relationships are discussed including docking results obtained for 4-anilino alpha-carbolines. A first profiling of selective kinase inhibition and a proof of concept for the antiproliferative effects is demonstrated. These results qualify the compounds as a promising class of novel antitumor agents. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.002

文献信息

• Discovery of 4-anilino α-carbolines as novel Brk inhibitors
  作者：Kazem Ahmed Mahmoud、Martin Krug、Tom Wersig、Inna Slynko、Christoph Schächtele、Frank Totzke、Wolfgang Sippl、Andreas Hilgeroth

  DOI：10.1016/j.bmcl.2014.03.002

  日期：2014.4

  Dysregulation of cell signalling processes caused by an enhanced activity of protein kinases mainly contributes to cancer progression. Protein kinase inhibitors have been established as promising drugs that inhibit such overactive protein kinases in cancer cells. The formation of metastases, which makes a therapy difficult, remains a great challenge for cancer treatment. Recently, breast tumor kinase (Brk) was discovered as novel and interesting target for a cancer therapy because Brk participates in both cell dysregulation and metastasis. We discovered 4-anilino substituted a-carboline compounds as a novel class of highly active Brk inhibitors. In the current work, structure-activity relationships are discussed including docking results obtained for 4-anilino alpha-carbolines. A first profiling of selective kinase inhibition and a proof of concept for the antiproliferative effects is demonstrated. These results qualify the compounds as a promising class of novel antitumor agents. (c) 2014 Elsevier Ltd. All rights reserved.